Page 23 - Pharma Sector

USFDA issues 3 observations to Gland Pharma Hyderabad Unit, stock down 6%

The inspection at the Hyderabad facility took place between July 25, 2024 and August 02, 2024.

Reading the vital signs: Pharma sector, the market's trusted antidote

The pharma index was the only healthy pulse amid Friday's market declines

Govt agencies conducting risk-based inspections of pharma units: Nadda

Over 400 drug manufacturing units, including MSMEs, inspected after high frequency of NQS reports

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Ajanta Pharma Q1 results: PAT up 18% to Rs 246 cr on robust sales

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.

USFDA scrutiny delays generic drug approvals for major Indian pharma firms

Big Pharma companies Cipla, Sun Pharma, Aurobindo Pharma, Dr Reddy's, and Lupin face intense scrutiny from the US Food and Drug Administration (USFDA)

Sanofi India stock falls 2% on weak June quarter results; profit falls 16%

The fall in the share price came after the pharmaceutical company reported a weak set of June quarter of financial year 2025 (Q1FY25) results.

USAID, Takeda Biopharma launch dengue prevention programme across India

The vaccine is already available for children and adults in the private market in Europe, Indonesia, and Thailand, and in some public programmes in Argentina and Brazil

Dr Reddy's Laboratories Q1 result: Net profit dips 0.90%, revenue up 13.88%

DRL's growth was primarily driven by the robust performance of the global generics business, particularly in North America and India

Sun Pharma Q1 Preview: R&D spends to hit margins; profits may rise 10%

Brokerages expect a satisfactory quarter for Sun Pharma giant with a steady growth in the topline as well as bottomline on a year-on-year (YoY) basis, however, sequentially the bottomline may get hit

Thyrocare expands Northern India presence with Polo Labs acquisition

This move will lead to Thyrocare integrating Polo Labs' 14 laboratories spread across Punjab, Haryana, and Himachal Pradesh into its existing network

India may have dengue vaccine by 2026; Takeda initiates clinical trials

Takeda follows a dual pricing strategy in both private and public markets, and as such, prices in the private market are higher in Europe than in Asian markets

Mankind Pharma frontrunner to acquire Bharat Serums in $1.5 bn deal

Mankind Pharma rose as much as 1.2 per cent following Thursday's Bloomberg News report. The shares are up about 6.5 per cent this year and 10 per cent in the past 12 months

Australia's Mayne Pharma sues Sun Pharma over patent infringement

In the lawsuit filed at the United States District Court for New Jersey, Mayne Pharma accused its rival of violating all 20 Orange Book-listed patents linked to IMVEXXY

Torrent Pharma tanks 4% post Q1FY25 results; analysts update target prices

Shares of Torrent Pharma slumped up to 4.26 per cent at Rs 646.70 per share on the BSE in Tuesday's intraday deals. This came despite the Indian drugmaker delivering a strong April-June quarter

IOL Chemicals zooms 5% on drug nod from European regulator: details here

OL Chemicals and Pharmaceuticals stock surged up to 4.59 per cent at Rs 415.15 per share on the BSE in Wednesday's intraday trade

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

US Biosecure Act spells long-term boost for Indian CDMO, CRO firms

As American biopharma looks to diversify sourcing, Indian companies stand to benefit

Zydus Life Vadodara facility gets OAI report from USFDA, stock falls 3%

The fall in the stock came after the company announced that it has secured an Official Action Indicated (OAI) report from the United States Food and Drug Administration (USFDA).

Aurobindo Pharma board approves share buyback plan worth Rs 750 cr

Aurobindo Pharma on Thursday said its board has approved a share buyback plan of up to Rs 750 crore. The company's board has approved the buyback of up to 51,36,986 shares representing up to 0.88 per cent of the total paid-up equity share capital, Aurobindo Pharma said in a regulatory filing. The company will buy the shares at Rs 1,460 apiece for an aggregate amount of up to Rs 750 crore, it added. The drug firm said July 30 has been fixed as the record date for the Rs 750-crore share buyback scheme through the tender offer route. At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively. Shares of Aurobindo Pharma were trading 2.83 per cent down at Rs 1,332.90 apiece on the BSE.